Page 15 - Flipbook
P. 15
nmCRPC
CRPC = disease progression despite ADT and castrate level of
testosterone (<1.7 nmoL/L)
Progression is biochemical in the absence of metastatic disease
(nmCRPC)
◦ PSA rise with minimum value of 2.0 ng/mL measured at least 1week apart
◦ PSADT should be assessed by using at least 3 values measured at least 4 weeks
apart
◦ If PSADT is less than 10 months, risk of progression to metastasis is considered
high and long term data 3 pivotal RCTs support the use of NHAs in addition to ADT
in prolonging survival
